Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-92480 + bortezomib + dexamethasone versus pomalidomide + bortezomib + dexamethasone in relapsed or refractory multiple myeloma
2021-001957-30Phase 3Active
- Sponsor
- Celgene Corporation
- Start
- Jun 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mezigdomide, pomalidomide, bortezomib and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Progression-free survival. Started Jun 2022; status: active.
02
Drugs
mezigdomidepomalidomidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2021-001957-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001957-30.